Predictors of osimertinib response at second-line treatment in EGFR mutant non-small cell lung cancer patients with acquired T790M resistance mutation

被引：0
|
作者：
Dogan, I. [1 ]
Gurbuz, M. [2 ]
Paksoy, N. [1 ]
Khanmamadov, N. [1 ]
Vatansever, S. [1 ]
Saip, P. [1 ]
Demirkazik, A. [2 ]
Aydiner, A. [1 ]
机构：
[1] Istanbul Univ, Med Oncol, Inst Oncol, Istanbul, Turkey
[2] Ankara Univ, Med Oncol, Fac Med, Ankara, Turkey
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.2015
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
19P
引用
收藏
页码：S1351 / S1351
页数：1
相关论文
共 50 条
  • [1] Mixed Response of Non-Small Cell Lung Cancer Harboring the EGFR T790M Mutation to Osimertinib
    Shinno, Y.
    Goto, Y.
    Sato, J.
    Morita, R.
    Matsumoto, Y.
    Murakami, S.
    Kanda, S.
    Horinouchi, H.
    Fujiwara, Y.
    Yamamoto, N.
    Ohe, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2145 - S2145
  • [2] Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer
    Soejima, Kenzo
    Yasuda, Hiroyuki
    Hirano, Toshiyuki
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (01) : 31 - 38
  • [3] Osimertinib for the Treatment of Metastatic EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer
    Khozin, Sean
    Weinstock, Chana
    Blumenthal, Gideon M.
    Cheng, Joyce
    He, Kun
    Zhuang, Luning
    Zhao, Hong
    Charlab, Rosane
    Fan, Ingrid
    Keegan, Patricia
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2017, 23 (09) : 2131 - 2135
  • [4] EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients
    Zheng, Qiufan
    Hong, Shaodong
    Huang, Yan
    Zhao, Hongyun
    Yang, Yunpeng
    Hou, Xue
    Zhao, Yuanyuan
    Ma, Yuxiang
    Zhou, Ting
    Zhang, Yaxiong
    Fang, Wenfeng
    Zhang, Li
    CLINICAL AND TRANSLATIONAL MEDICINE, 2020, 9 (01):
  • [5] The correlation between the abundance of EGFR T790M mutation and osimertinib response in advanced non-small cell lung cancer
    Pan, Guoqiang
    Chen, Kaiyan
    Yu, Xiaoqing
    Sheng, Jiamin
    Fan, Yun
    TRANSLATIONAL CANCER RESEARCH, 2021, 10 (06) : 2895 - 2905
  • [6] Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients
    Liao, Bin-Chi
    Griesing, Sebastian
    Yang, James Chih-Hsin
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11
  • [7] Resistant Patterns to Osimertinib in Non-Small Cell Lung Cancer Patients with Both T790M and Sensitizing EGFR Mutation
    Lee, J. C.
    Yang, S.
    Oh, D. K.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S806 - S807
  • [8] Impact of T790M Mutation Status on Later-Line Osimertinib Treatment in Non-Small Cell Lung Cancer Patients
    Tang, Yan-Jei
    Chang, John Wen-Cheng
    Chang, Ching-Fu
    Huang, Chen-Yang
    Yang, Cheng-Ta
    Kuo, Chih-Hsi Scott
    Fang, Yueh-Fu
    Hsu, Ping-Chih
    Wu, Chiao-En
    CANCERS, 2022, 14 (20)
  • [9] Targeting the Gatekeeper: Osimertinib in EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer
    Skoulidis, Ferdinandos
    Papadimitrakopoulou, Vassiliki A.
    CLINICAL CANCER RESEARCH, 2017, 23 (03) : 618 - 622
  • [10] Different characteristics and survival in non-small cell lung cancer patients with primary and acquired EGFR T790M mutation
    Wang, Shuyuan
    Yan, Bo
    Zhang, Yanwei
    Xu, Jianlin
    Qiao, Rong
    Dong, Yu
    Zhang, Bo
    Zhao, Yiming
    Zhang, Lele
    Qian, Jie
    Lu, Jun
    Zhao, Ruiying
    Han, Baohui
    INTERNATIONAL JOURNAL OF CANCER, 2019, 144 (11) : 2880 - 2886
12345